We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
161 hedge funds and large institutions have $1.22B invested in AbCellera Biologics in 2022 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 53 increasing their positions, 28 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
157% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 21
89% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 28
87% more call options, than puts
Call options by funds: $35.3M | Put options by funds: $18.9M
24% more funds holding
Funds holding: 130 → 161 (+31)
10% more capital invested
Capital invested by funds: $1.1B → $1.22B (+$112M)
1.55% more ownership
Funds ownership: 39.97% → 41.52% (+1.6%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Holders
161
Holders Change
+31
Holders Change %
+23.85%
% of All Funds
2.71%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.12%
New
54
Increased
53
Reduced
28
Closed
21
Calls
$35.3M
Puts
$18.9M
Net Calls
+$16.4M
Net Calls Change
-$2.69M
Top Buyers
| 1 |
BlackRock
New York
|
+$79.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.8M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$19.5M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.6M |
| 5 |
Millennium Management
New York
|
+$12.4M |
